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Integrin-linked kinase (ILK) is a serine/threonine protein kinase which interacts with the cytoplasmic domains of h1 and h3 integrins. ILK
structure and its localization at the focal adhesion allows it not only to interact with different structural proteins, but also to mediate many
different signalling pathways. Extracellular matrices (ECM) and growth factors each stimulate ILK signalling. Constitutive activation of ILK
in epithelial cells results in oncogenic phenotypes such as disruption of cell extracellular matrix and cell to cell interactions, suppression of
suspension-induced apoptosis, and induction of anchorage independent cell growth and cell cycle progression. More specifically,
pathological overexpression of ILK results in down-regulation of E-cadherin expression, and nuclear accumulation of h-catenin, leading to
the subsequent activation of the h-catenin/Tcf transcription complex, the downstream components of the Wnt signalling pathway. Here we
review the data implicating ILK in the regulation of these two signalling pathways, and discuss recent novel insights into the molecular basis
and requirement of ILK in the process of epithelial to mesenchymal transformation (EMT).
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E-cadherin, an epithelial adhesion protein, and h-cate-
nin, its cytoplasmic mediator, which also acts as the
penultimate downstream component of the Wnt signalling
pathway, are two of the many proteins regulated by
signalling through integrin-linked kinase (ILK). ILK is a
serine-threonine kinase that is ubiquitously expressed in
mammalian cells [1]. ILK was first identified based on its
interaction with the cytoplasmic domain of h1 integrin
subunit using a yeast two-hybrid screen [1]. Subsequent
co-immunoprecipitaion studies confirmed this interaction,
and also demonstrated that ILK can interact with the
cytoplasmic tail of h3-integrin subunit [1]. Since its iden-
tification, numerous other binding proteins and signalling
functions have been attributed to ILK in a variety of cellular
systems and contexts.0167-4889/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
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ILK is composed of three highly conserved structurally
and functionally distinct domains [1–4] (Fig. 1). The N-
terminus of ILK contains four ankyrin repeats (ANK), which
allow its interaction with the LIM domain-containing adapter
protein PINCH [3]. PINCH appears to regulate the localiza-
tion of ILK to focal adhesion plaques where it transduces
downstream signalling via its Ser/Thr protein kinase activity
[5]. In addition, PINCH links ILK to growth factor receptors
and phosphatidylinositol-3 (Pi3K) via its interaction with
Nck-2 [3]. The ANK repeats also mediate ILK interaction
with ILKAP, a PP2C phosphatase that negatively regulates
ILK kinase activity [6]. C-terminal to the ANK domain is the
pleckstrin homology (PH)-like motif that has been shown to
bind the product of Pi3K, phosphatidylinositol 3,4,5-triphos-
phate (PIP3) [3,4,7]. The PH-like motif partly overlaps the C-
terminal domain, which contains a protein kinase catalytic
site that exhibits significant homology to other protein kinase
catalytic domains [1,8]. However, differences in three sets of
motifs in the kinase domain lead to the speculation that ILK
may not possess kinase activity, or that the molecular
Fig. 1. ILK structure and binding proteins. ILK binds integrins and complexes to the actin cytoskeleton via parvins and paxillin. The binding of a-parvin
stimulates ILK activity and promotes phosphorylation of PKB/Akt on Ser 473. PINCH binds to the ANK repeat of ILK, and further promotes the localization
of ILK to focal adhesions. ILK activity maintains localization of paxillin and a-parvin to focal adhesion.
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kinases. The kinase activity of ILK was first demonstrated by
its ability to readily phosphorylate peptides and model
substrates such as myelin basic protein (MBP) in vitro [1],
and to induce phosphorylation of the protein kinases PKB/
Akt and GSK-3h in cells overexpressing ILK [4]. In addition
to the kinase domain, the C-terminal domain of ILK contains
binding sites for h-integrins, and at least three different
cytoplasmic adaptor proteins that mediate the connection
of integrins to the actin cytoskeleton (reviewed in Ref. [8])
(Fig. 1). a-Parvin/CH-ILKBP/actopaxin was identified in a
yeast two-hybrid genetic screen based on its interaction with
the C-terminal domain of ILK [9]. h-parvin/Affixin, signif-
icantly homologous to a-parvin, was found to bind ILK via
its CH2 domain [10], and Paxillin binds ILK via its LD1
domain [11]. h-parvin is believed to be important in the
initiation of the focal adhesion formation, and in linking
integrin-ILK signalling to focal adhesion formation [10]. The
functional interaction between ILK [11], a-parvin, as well as
Paxillin [12] has also been shown to be mutually important
for the localization of these proteins to focal adhesions. In
addition, the interaction with a-parvin regulates ILK activity
and downstream signalling to PKB/Akt and GSK-3h [12].
The interaction of ILK with these proteins emphasizes its
crucial role as an adapter protein linking integrins, receptor
tyrosine kinases and the actin cytoskeleton.
1.2. Biological effects of signalling through ILK
Since its identification, ILK has been found to be crucial
in many different biological processes such as proliferation,migration, angiogenesis and survival by transducing signals
from ECM components and growth factors to downstream
signalling components. The kinase activity of ILK is stim-
ulated rapidly and transiently by the engagement of integ-
rins to the extracellular matrix (ECM) [13–15], or
stimulation of receptor tyrosine kinases by certain growth
factors [4,14]. This stimulation appears to be Pi3K-depen-
dent, and involves binding of PIP3 to the PH-like domain
[8,13,15]. Therefore, ILK is considered to be an important
component of the Pi3K signalling pathway, which impli-
cates ILK in a wide range of cellular processes. The activity
of ILK is also negatively regulated by two phosphatases:
PTEN, a tumour suppressor lipid phosphatase which
dephosphorylates PIP3 to PIP2, and ILKAP, a PP2C protein
phosphatase [6,16,17]. ILK has been shown to be constitu-
tively active in PTEN null tumour cells [16,18]. Despite the
divergence in homology at three motifs in the kinase domain
of ILK compared to other active kinases [1,19,20], ILK has
been shown to directly phosphorylate several proteins.
These include PKB/Akt on Ser 473 [16,21], GSK-3h on
Ser 9 [18], myosin light chain kinase on both Ser 18 and Thr
19 [22], and affixin [10].
The analysis of the role of ILK in stimulating various
signalling pathways has been achieved by constitutive
activation and/or overexpression in epithelial cells, and
stimulation using growth factors, as well as loss of function
strategies such as transfection with dominant negative (DN)-
ILK, small molecular ILK inhibitors, and more recently ILK
siRNA (small interfering RNA) [21]. These studies have
revealed a critical role for ILK in the stimulation of the
downstream components of many key signalling pathways.
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phorylation of both PKB/Akt and GSK-3h, resulting in the
activation of the former and inactivation of the latter. ILK
activation of PKB/Akt by phosphorylation on Ser 473 has
been considered to be significant, since the implication of
Akt in a variety of cell signalling pathways such as cell
survival, cell cycle progression, transcriptional regulation
and protein translation has been reported (reviewed in Ref.
[23]). In keratinocytes, modulation of the activation of PKB/
Akt by PPARh has also been recently shown to be in part
due to the transcriptional up-regulation of ILK [24].
The inhibition of GSK-3h by ILK results in the activa-
tion of the transcription factor AP-1 by phosphorylating one
of its components, c-jun [25–30]. The induction of AP-1 by
ILK also results in the stimulation of the expression of
matrix metalloproteinase, MMP-9 [29], which implicates
ILK in the process of invasion and metastasis. Another
phenotype of ILK overexpression that supports its role in
invasion is loss of cell to cell adhesion [14,31], and
stimulation of anchorage-independent growth [32,33]. The
inhibition of GSK-3h by ILK could also lead to the
stabilization of h-catenin followed by an increase in h-
catenin/Tcf transcriptional activity [4,13,29,30,34], which
will be discussed in detail in the following sections. ILK-
mediated inhibition of GSK-3h results in the induction of
yet another transcription factor, CREB, which together with
AP-1 and h-catenin/Tcf may be responsible for the ultimate
overexpression of cyclin D1 [35]. ILK has also been shown
to stimulate the expression of iNOS and COX-2 in an NF-
nB-dependent manner [36].
Genetic knock out of ILK either systematically or in a
tissue-specific manner has demonstrated a crucial role for
ILK at a very early embryonic stage, specifically during
blastocyst implantation [37]. Analysis of ILK null embryonic
stem cells has revealed its involvement in actin polymeriza-
tion and cell polarization [37]. Although phosphorylations of
PKB/Akt on serine 473 and GSK-3 on serine 9 are not
affected in ILK-null embryonic stem cells [37], significantly
reduced levels of phosphorylated PKB/Akt and GSK-3 as
well as reduced levels of cyclin D1 are observed in ILK null
macrophages [21] and endothelial cells (unpublished data
and Ref. [38]). These data suggest a cell type- and tissue-
specific role of ILK in the regulation of these effector
proteins. Furthermore, conditional knock out of ILK in
chondrocytes has shown that ILK is critical in chondrocyte
proliferation and control of cyclin D1/D2 expression [39,40].
The oncogenic properties of ILK overexpression in epi-
thelial cells have been associated with increased fibronectin
matrix deposition, down-regulation of E-cadherin expres-
sion, and nuclear translocation of h-catenin, which are the
main focus of this review [31,33,41]. These properties could
be considered as hallmarks of ILK overexpression in epithe-
lial cells, and have been associated with a highly invasive
phenotype, and with epithelial to mesenchymal transforma-
tion (EMT) [41,42], as well as both in vitro and in vivo
oncogenic transformation [14,42]. Utilizing siRNA andpharmacological inhibitors, ILK has also recently been
shown to regulate tumour angiogenesis [38]. ILK mRNA
and protein levels have also been examined in a variety of
human cancers, and have been correlated with the disease
outcome [43–47].2. The role of ILK in the regulation of E-cadherin
2.1. E-cadherin structure and function
E-cadherin is a tumour suppressor that is emerging as
one of the caretakers of the epithelial phenotype [48]. The
loss or down-regulation of E-cadherin has been frequently
reported in metastatic and invasive carcinomas [49], and is
hypothesized to be a critical, but not sufficient, step in the
induction of an epithelial to mesenchymal transition
(EMT) [50]. E-cadherin is a type I cadherin transmem-
brane glycoprotein that is specifically expressed on the
surface of epithelial cells, where it mediates the formation
of cell to cell adherin junctions, via a homophilic, calcium-
dependent interaction [51–53]. The formation and mainte-
nance of adherin junctions are important in the develop-
ment and maintenance of epithelial tissues [54–59].
Therefore, dysregulation of E-cadherin could have pro-
found effects on epithelial tissue structure and function.
The extracellular domain of E-cadherin mediates the
homophilic interaction, while the intracellular region medi-
ates its interaction with the actin cytoskeleton, via mem-
bers of the catenin family [60–63]. Besides playing a
crucial role in cell to cell adhesion, E-cadherin is also
critical in the transfer of information intracellularly via its
interactions with the actin cytoskeleton and various sig-
nalling molecules, such as h-catenin. Therefore, an under-
standing of the mechanism which regulate the function and
expression of E-cadherin is critical for the understanding
of invasion, metastasis and EMT. A number of studies
have implicated ILK in the regulation of E-cadherin
expression [14,31,34,41,64].
2.2. ILK and E-cadherin
A role for ILK in the regulation of E-cadherin expression
was first identified in the IEC-18 rat intestinal and Scp2
mousemammary epithelial cell lines. Overexpression of ILK,
but not kinase-deficient or antisense ILK, in IEC-18, Scp2
and human renal tubular epithelial cells has been shown to
result in the loss of E-cadherin expression, and the acquisition
of a fibroblastic morphology [14,31,34,41,64,65]. This role
was further supported by the observation that the inhibition of
ILK activity in human cancer cell lines results in the up-
regulation of E-cadherin expression. In the E-cadherin low
SW480 human colon carcinoma cell line, inhibiting ILK
activity, with either a dominant negative ILK construct or a
specific small molecule ILK inhibitor, results in an up-
regulation of E-cadherin expression [34]. In the PTEN null,
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reexpression of PTEN, a Pi3K antagonist, results in the
reexpression of E-cadherin [18]. As previously described,
ILK activity is Pi3K-dependent; therefore, this suggests that
the loss or down-regulation of E-cadherin in some carcinoma
cell lines is due to high ILK activity. E-cadherin appears to be
transcriptionally regulated by ILK [34,41]. The overexpres-
sion of wild-type ILK, but not the kinase-deficient or anti-
sense constructs, in the IEC-18 cells has been shown to
decrease the promoter activity of E-cadherin, whereas the
inhibition of ILK in SW480 cells increases the promoter
activity of E-cadherin [34]. Therefore, the inhibition of E-
cadherin transcription is hypothesized to be the key mecha-
nism by which ILK regulates E-cadherin levels. In human
kidney proximal tubular and renal tubular epithelium, ILK
has recently been shown to be critical in EMT induced by
TGF-h1 [65]. TGF-h1 stimulates up-regulation of ILK
expression that results in the induction of EMT. Therefore,
at basal levels ILK does not affect the regulation of E-
cadherin. However, when ILK is overexpressed or is highly
active, it could cause pathological conditions through the
down-regulation of E-cadherin.
2.3. E-cadherin transcriptional regulation
The transcription of E-cadherin is controlled by both
positive and negative regulatory elements located in its 5V
promoter region [66–69]. The positive regulatory regions of
E-cadherin consist of a CCAAT-box and a GC-rich region
that contains two AP-2 binding sites [67]. The 5Vpromoter
region also contains three E-box motifs, protein binding
motifs with a core consensus sequence of CANNTG
[64,66,70–72], which have both negative and positive
regulatory functions. The E-box motifs function as negative
regulators of E-cadherin in mesenchymal and transformed
cells by binding transcriptional repressors, such as the Snail
[64,66,70,71,73,74] and Zeb [64,75] families of zinc finger
proteins and the E12/47 basic helix loop helix (bHLH)
protein [76]. The E-box motifs are also believed to have
positive regulatory function in epithelial cells, since their
deletion in an E-cadherin luciferase reporter has been shown
to abolish promoter activity [69]. This positive regulatory
function is hypothesized to be mediated by bHLH transcrip-
tion factors that are known to bind E-box motifs and
promote transcription [70].
In a majority of carcinomas, the loss of E-cadherin is not
due to mutation, but due to dysregulation of transcription
factors, or promoter hypermethylation [69,70,77,78]. Al-
though the loss of E-cadherin is beneficial to tumours for
invasion and metastasis, it may also trigger apoptosis. There-
fore, maintaining a reversible mechanism of transcriptional
control could be advantageous in tumourigenesis [79]. In
epithelial cells the inactivation of Retinoblastoma (RB) by
simian virus 40 large T antigen (LT) resulted in the down-
regulation of c-Myc, E-cadherin and other epithelial markers,
and the induction of EMT [80]. Interestingly, the ectopicexpression of RB or c-Myc resulted in an increase in E-
cadherin and other epithelial markers in epithelial cells, but
not in mesenchymal cells or fibroblasts [80], suggesting the
presence of a dominant repression pathway in these cells.
Analysis of somatic cell hybrids of E-cadherin-positive and
-negative breast cancer cells suggests that the loss of E-
cadherin expression in some breast cancers is also due to a
dominant repression pathway and that this mechanism is
trans-acting [81]. These observations implicate transcrip-
tional repressors as the mechanism that down-regulates E-
cadherin expression in mesenchymal cells, fibroblasts and
E-cadherin negative carcinomas. Numerous E-cadherin
repressors have been identified with the members of the
Snail and Zeb families of proteins, and the E12/E47 basic
helix loop helix (bHLH) transcription factor being of
particular interest.
2.4. Transcriptional factors involved in E-cadherin
repression
A key role for the Snail family in the repression of E-
cadherin expression during development and progression of
carcinomas has clearly been demonstrated in numerous cell
systems and biological contexts. The Snail family members
are highly homologous zinc finger proteins that function as
transcriptional repressors [82]. The zinc fingers, located in
the C-terminus, mediate the sequence specific DNA binding
to the E-box consensus sequence of CANNTG [66,70,82–
86], which is essential for its repressor activity [66,70,84,
85,87–92]. It is hypothesized that the repressor function of
the Snail proteins is partially mediated via its competition
with the bHLH transcription factors to bind the E-box motif
[72,84,90]. Although the repressor activity depends greatly
on the zinc finger region, at least two other regions in the N-
terminus are important for the repressor function. The
SNAG (Snail/Gfi) domain is conserved in the N-terminal
region of all vertebrate Snail genes, and has been shown to
be important for the repressor function of the Snail proteins
in mammalian cells [84]. Several vertebrate Snail family
members also contain a partial CtBP interaction domain
(CID) consensus sequence. The transcriptional repressor
role of the Snail family of proteins is therefore mediated
by its ability to compete for regulatory elements in the E-
cadherin promoter, the SNAG domain, its interaction with
CtBP, or a combination of the three. Current evidence
strongly suggests a role for two members of the Snail
family, Snail-1 (Sna-1) and Slug (Sna-2), in the down-
regulation of E-cadherin expression [66,70,71].
The exogenous expression of Snail-1 in epithelial cells
results in the dramatic down-regulation of E-cadherin, con-
version to a fibroblastic phenotype, and acquisition of
tumourigenic and invasive properties [66,70,82]. High
Snail-1 levels are also detected in both mouse and human
carcinoma cell lines that lack E-cadherin expression
[66,70,74,79,82,93], suggesting a role for Snail-1 in the
regulation of E-cadherin in carcinogenesis. Snail-1 is critical
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mesoderm and in tissues undergoing EMT, and it inversely
correlates with the expression of E-cadherin [73]. The Snail-1
knockout mice are embryonic lethal, being unable to undergo
gastrulation due to the inability to down-regulate E-cadherin
and undergo EMT [73]. In addition, Snail-1 regulates the
expression of epithelial and mesenchymal specific proteins.
Epithelial markers such as desmoplakins [66], cytokeratin 18
and MUC1 [64] are down-regulated, and mesenchymal
markers such as LEF1 [64], vimentin [66] and fibronectin
[64,66] are up-regulated which could ultimately result in the
redistribution of h-catenin from the plasma membrane to the
cytosol and nucleus [66]. Interestingly, Snail-1 expression
also results in the up-regulation of another E-cadherin tran-
scriptional repressor, Zeb-1[64], a zinc finger homeodomain
protein. The transcriptional repression obtained with Zeb-1 is
comparable to Snail-1, but requires a 10–20-fold higher
concentration [64]. The transcription of Zeb-1 is regulated
by Snail-1, and therefore there is a temporal delay in its
expression as compared to Snail-1[64]. However, the expres-
sion of Zeb-1 persists after Snail-1 expression is lost
[64,94,95], implicating it in maintenance, but not induction
of the mesenchymal phenotype [94]. Snail-1 is capable of
regulating E-cadherin and initiating complete EMT in vitro,
and is critical in developmental processes. Therefore, Snail-1
is a strong candidate for initiating E-cadherin repression,
progression of EMT and cancer metastasis.
Slug was first identified as another repressor of E-cadherin
in chicken, where it was shown to be critical in the induction
of EMT during embryonic development [96]. However, this
role is not maintained in all vertebrates. The expression of
Slug does not correlate with the loss of E-cadherin expression
or EMT during mouse embryogenesis [66,97], and unlike
Snail, Slug null mice are viable and fertile [97]. However,
Slug expression has been correlated with the loss of E-
cadherin in human breast carcinomas [71]. While overex-
pression of Slug in some epithelial cell lines resulted in the
down-regulation of E-cadherin [71], in NBT-II rat bladder
carcinomas cells, Slug overexpression did not result in the
loss of E-cadherin, but it down-regulated components of the
desmosomes, another cell to cell adhesion complex [87].
Although a probable role for Slug has been proposed in EMT,
current evidence suggests that it is unlikely, except in specific
cellular contexts.
2.5. E-cadherin transcriptional repressors and ILK
Overexpression of ILK in epithelial cells can induce
EMT, likely via the transcriptional regulation of members
of the Snail and Zeb families of transcriptional repressors.
ILK regulates E-cadherin at the transcriptional level, and
this repression of E-cadherin transcription was shown to be
likely mediated by Snail-1[34,64] (Fig. 2A and B). The
inhibition of ILK in SW480 cells has been shown to result
in the down-regulation of the activity of the 5V Snail-1
promoter, concomitant with the up-regulation of the activ-ity of the 5VE-cadherin promoter [34]. Further analysis of
the Snail-1 promoter identified the major ILK responsive
element, termed the SIRE (Snail ILK responsive element),
which is located within the  134 to  69 region of the
Snail-1 promoter [34]. Therefore, identification of proteins
capable of binding the SIRE and regulating Snail-1 tran-
scription is critical to elucidate the mechanics by which
ILK regulates Snail-1 and E-cadherin. An intriguing can-
didate has recently been identified that could be an
important link between ILK and Snail. Metastasis factor
3 (MTA3) was identified as a component of an inhibitory
complex that binds the upstream promoter of Snail. MTA3
expression was shown to be up-regulated indirectly by the
Estrogen Receptor, and preliminary results from our labo-
ratory indicate that MTA3 expression is inhibited by ILK
(unpublished data). Regulation of Snail-1 by ILK has been
demonstrated in the IEC-18 epithelial cell lines. Over-
expression of ILK, but not the kinase-deficient or antisense
constructs, results in an increase in Snail-1 mRNA levels
and promoter activity [34,64]. Therefore, MTA3 may
function independently of estrogen signalling, or other
unidentified proteins may mediate the regulation of
Snail-1 by ILK.
TGF-h1 signalling has also been implicated in the regu-
lation of E-cadherin, Snail-1 and EMT [98–103]. Previously
the MAPK and Pi3K pathways have been shown to transduce
this effect by stimulating morphological changes and surviv-
al, respectfully [104,105]. Recently it was discovered that the
engagement of integrins stimulated the expression and se-
cretion of TGF-h1. The up-regulation of TGF-h1 expression
and secretion is shown to be dependent upon the activity of
ILK, but not focal adhesion kinase (FAK) [106]. This leads to
the speculation that in vivo EMT stimulated by TGF-h1 is
dependent on ILK signalling in order to retain the presence of
TGF-h1 ligand, and the mesenchymal phenotype. In renal
tubular epithelial cells, ILK expression is up-regulated in a
dose- and time-dependent manner by TGF-h1 signalling in a
Smad-dependent manner [65]. EMT has been shown to be
mediated by ILK signalling in these cells, since the expres-
sion of a dominant negative, but not a wild-type, ILK
construct blocks this TGF-h1-initiated EMT [65]. In addi-
tion, ectopic expression of wild-type ILK in these cells results
in a complete EMT, which phenotypically resembles the one
initiated by TGF-h1[65]. In this case, however, the suppres-
sion of E-cadherin expression by ILK may be Snail-1-
independent. One characteristic of EMT is the increased
expression and assembly of fibronectin, which engages
integrins and stimulates ILK activity [13–15]. The engage-
ment of integrins has been shown to stimulate the expression
and secretion of TGF-h1 in an ILK-dependent manner,
therefore, it is possible that ILK and TGF-h1 could form a
positive feedback autocrine loop (Fig. 3).
In addition to Snail-1, Zeb-1 is another transcriptional
repressor up-regulated in IEC-18 cells overexpressing ILK
[64]. Current evidence suggests that Zeb-1 plays a role in
the maintenance of E-cadherin transcription, and in the
Fig. 2. (A) In normal somatic epithelial cells, ILK expression and activity are at basal level. The expression of the snail repressor, MTA3, maintains low levels
of Snail, resulting in E-cadherin expression, and formation and maintenance of adherence junctions. (B) Under pathological conditions, E-cadherin levels are
suppressed due to ILK activation via constitutive activation of Pi3K pathway, for example by mutation or loss of expression of the tumor suppressor PTEN, or
ILK up-regulation by TGF-h [65]. ILK activation or overexpression can inhibit MTA-3 expression, resulting in the stimulation of the E-cadherin transcriptional
repressor, Snail. Adherence junctions are disrupted, resulting in the promotion of EMT.
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EMT [64]. ILK indirectly regulates the transcription of Zeb-
1 via Snail [64], but this does not rule out the possibility that
ILK may also directly regulate Zeb-1. Further analysis of
the relationship between ILK, Snail-1 and Zeb-1 is neededto elucidate the details of this signalling cascade. There is
currently no evidence to support a link between ILK
signalling and the Snail family protein Slug, the Zeb family
protein Zeb-2, or the bHLH protein E47 in the regulation of
E-cadherin and EMT.
Fig. 3. ILK/TGF-h autocrine feedback loop and EMT. A positive autocrine
feedback loop can be envisaged in the maintenance of EMT. TGF-h
stimulates ILK expression, which in turn represses E-cadherin expression,
but stimulates the expression of fibronectin (FN), MMP-2 and MMP-9. ILK
not only stimulates FN stimulation, but also promotes its assembly. Integrin
engagement by RGD containing ligands such as fibronectin results in further
stimulation of TGF-h expression in an ILK-dependent manner [106].
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through the up-regulation of LEF-1. Overexpression of
LEF-1 has been shown to outcompete E-cadherin for h-
catenin binding, thus disrupting cadherin/catenin complexes
and resulting in the internalization of E-cadherin followed
by its degradation [107]. Therefore, in addition to its direct
effect on repressing the transcription of E-cadherin, ILK
could increase the degradation of E-cadherin, which nor-
mally has a half life of 5–7 h, via the up-regulation of LEF-
1 [108,109]. However, this is yet to be examined.3. The role of ILK in EMT
EMT is a critical process in embryonic development
and is hypothesized to be involved in the invasion and
metastasis of carcinomas [48,66,70,110]. Epithelial cells
are characterized by an apical basal polarity, an inability to
migrate, and close linkages to both adjacent cells and the
ECM [111,112]. In contrast, mesenchymal cells are char-
acterized by a front end back end polarity, an ability to
migrate through the ECM, and a lack of close linkages to
the ECM or adjacent cells [48,112]. EMT is a mechanism
by which epithelial cells, generated in a particular region,
can transform to a mesenchymal phenotype, dissociate
from the epithelium and migrate to secondary sites [110].
It is characterized by alterations in cell to cell adhesion,
cell to ECM interactions, ECM degradation and cytoskel-
etal organization [64,110,113]. In development, EMT is
critical for gastrulation, organogenesis and the migration of
neural crest cells [48,110]. Cells that undergo EMT may
revert to an epithelial phenotype, in a process termed
mesenchymal to epithelial transition (MET), or may retain
a mesenchymal phenotype [48,114,115]. During EMT,
epithelial genes, such as E-cadherin, are down-regulated
and mesenchymal genes are up-regulated [48,104,110].The dysregulation of epithelial and mesenchymal gene
expression distinguishes EMT from cell scattering, another
process in which cells depolarise and acquire a fibroblastic
morphology [104].
ILK can modulate the expression of not only E-cadherin,
but also other epithelial and mesenchymal genes. Therefore,
ILK is able to initiate a full EMT. The overexpression of
ILK in IEC-18 and Scp2 cells has been shown to result in
the down-regulation of the epithelial markers cytokeratin 18
[41] and MUC1[64], and the up-regulation of the mesen-
chymal markers LEF1 [31] and vimentin [31,64]. In addi-
tion, overexpression of ILK can stimulate fibronectin matrix
assembly [1,9,14], redistribution of h-catenin to the cyto-
plasm and nucleus [18], and induction of the transcription of
h-catenin/LEF1 target genes (see below) [31,34,116]. In the
inverse situation, the inhibition of ILK activity in SW480
cells down-regulates the expression of LEF-1 [34]. This
demonstrates that ILK can induce a complete EMT in
various epithelial cell lines. ILK signalling has been shown
to be critical in EMT in renal tubular epithelial cells, which
is believed to play a critical role in renal interstitial fibro-
genesis [65]. Therefore, ILK is involved in the initiation of
EMT in vivo, and the maintenance of the mesenchymal
phenotype and disease progression.4. ILK and B-catenin pathway
4.1. b-Catenin structure and function
h-Catenin is a 92-kDa protein, which, together with a-
and g-catenin (plackoglobin), was first isolated as a protein
associated with the cytoplasmic tail of E-cadherin. h-
Catenin links E-cadherin to a-catenin and, consequently,
the actin microfilament network of the cytoskeleton [117–
119]. The function of these E-cadherin associated mole-
cules was hypothesized to be in the linking of E-cadherin
to the cytoskeleton as their names, catenins (from catena,
the Latin word for chain) suggest. In fact, E-cadherin
exhibits its normal adhesive function when associated with
the catenins [120]. However, additional signalling func-
tions were suggested for h-catenin after it was cloned and
found to be the mammalian homologues of Drosophila
armadillo protein [121]. Armadillo has been identified as a
mediator in the wingless (wg) pathway involved in deter-
mining the segment polarity along the anterior posterior
axes of embryos [122]. The downstream signalling effect
of h-catenin is mediated through its interaction with the T
cell factor (Tcf) family of transcription factors leading to
activation of target genes.
The above two mentioned biological functions of h-
catenin also determine its cellular localization (Fig. 4A
and B) [123,124]. As a member of large molecular weight
complexes, h-catenin is involved in cell to cell adhesion at
the plasma membrane, and maintains the architecture of
epithelia. The free monomeric cytoplasmic pool, however,
Fig. 4. (A) In normal somatic epithelial cells, ILK expression and activity are at basal levels, and h-catenin is largely associated with E-cadherin and a-catenin.
Cytosolic h-catenin is degraded in a ubiquitin-mediated degradation pathway, requiring active GSK-3h, APC and axin. (B) In the presence of certain Wnt
proteins, or due to the loss of the tumor suppressors such as APC, axin and PTEN, GSK-3h activity is inhibited resulting in the inhibition of h-catenin
phosphorylation and inhibition of degradation. The resulting accumulation of h-catenin leads to the activation of LEF/Tcf transcription factors, which up-
regulate the expression of oncogenic and mesenchymal genes. Constitutive activation of ILK, for example via PiP3 accumulation in PTEN null cells, results in
the phosphorylation and inhibition of GKS-3h, and h-catenin stabilization. ILK activation or overexpression also results in the inhibition of E-cadherin
expression (see Fig. 2), leading to further accumulation of free h-catenin.
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tional activity in the nucleus. Although h-catenin does not
have a nuclear localization signal, its translocation to the
nucleus is achieved by binding to Tcfs after an increase in
the free cytoplasmic pool of h-catenin is induced by Wnt
signalling [123,124].
The regulation of h-catenin protein level is crucial for
signalling in multiple systems. Phosphorylation of h-catenin
by the serine/threonine protein kinase GSK-3h (glycogen
synthase kinase-3) is essential for the destabilization of this
protein. h-Catenin is phosphorylated by GSK-3h at multiple
site (three serines and one threonine) within the N-terminal
domain [125]. The phosphorylation of h-catenin by GSK-
3h in the absence of growth and differentiation signals
results in its ubiquitin proteosome-mediated degradation.
4.2. Tcf and its activation by b-catenin
Tcf/Lef transcription factors were originally discovered
independently by three different groups. Extensive experi-
ments indicated that members of Tcf/Lef family do not act
as classical transcription factors. That is, their ability to act
as transcription factors depend on the presence of additional
binding factors. Therefore, using a yeast two-hybrid genetic
screen, h-catenin was identified as one of the transactivators
of Tcf/Lef family of transcription factors [126] by binding to
their N-terminus. While Tcfs are sequence-specific DNA
binding proteins, h-catenin is the binding partner that
provides the transcriptional activation domains. Therefore,
Tcfs mediate signalling from Wg/Wnt by recruiting the non-
DNA binding h-catenin/Armadillo as a transcriptional acti-
vator. This finding positioned Tcfs in the Wnt/Wg cascade,
and provided the missing link of this pathway with target
genes in the nucleus (see below).
4.3. b-Catenin/Tcfs in the Wnt/Wg cascade
Wnt/Wg proteins are secreted glycoproteins, usually
350–400 amino acids in length, which play crucial roles
in regulating developmental processes in the mouse, Xen-
opus, C. elegans and Drosophila [127,128]. Wnt genes are
defined by sequence homology to the original members,
Wnt-1 in mouse and Wg in Drosophila. Wnt-1 (initially
termed Int-1, for integration-1) was isolated as an oncogene
whose activation upon the insertion of mouse mammary
tumour virus (MMTV) proviral DNA resulted in the forma-
tion of mouse mammary adenocarcinoma [129]. Deregu-
lated Wnt signalling is also considered a significant factor in
the development of several human cancers, such as breast
and colon tumourigenesis [130,131]. Overexpression of
several members of the Wnt family leads to morphological
transformation of mammary epithelial cells, such as C57MG
[132,133].Wnt genes are known to mediate multiple cellular
effects, and have been classified into two functional groups
with separate downstream signalling pathways. The Wnt-1
class stimulates the canonical Wnt/h-catenin pathway whilethe Wnt-5A group stimulates the Wnt/Ca2+ signalling path-
way (reviewed in Refs. [134,135]).
Insight into the mechanisms of Wnt signal transduction
has emerged from several systems: genetics in Drosophila
and C. elegans; biochemistry in cell culture and ectopic
gene expression in Xenopus embryos [127]. As currently
understood, these signalling molecules operate via activa-
tion of a receptor-mediated signalling pathway. Wnt proteins
are thought to interact with the seven transmembrane
receptors, frizzled, on the surface of target cells [134,136].
This interaction initiates hyperphosphorylation of the down-
stream novel phosphoprotein, Dishevelled (dsh) [134,137],
by an unknown mechanism, leading to the suppression of
GSK-3h, and subsequent stabilization of h-catenin
[134,137]. It is not known if the increase in free h-catenin
levels due to Wnt signalling can regulate E-cadherin func-
tion, but the disruption or loss of E-cadherin does affect the
levels of free h-catenin, which partially mimics or poten-
tiates Wnt signalling [138,139]. In the canonical Wnt
pathway, h-catenin mediates transcription of the target
genes via its interaction with Tcf/Lef family of co-activators
[135,140]. Activation of this transcriptional complex then
results in the expression of target genes such as cyclin D1,
c-myc and matrilysin [126,141–144].
In the absence of Wnt signalling, a degradation complex,
composed primarily of GSK-3h, Axin and adenomatous
polyposis coli (APC), phosphorylates h-catenin at multiple
sites, promoting its ubiquitination and subsequent degrada-
tion [131,145–149] (Fig. 4A). The structure of h-catenin
allows it to bind to several proteins such as APC, h-TrCP,
Axin/conductin, all of which aid in GSK-3h-mediated phos-
phorylation of h-catenin, and its ultimate degradation
[135,140,147,150,151]. APC and Axin are tumour suppres-
sor proteins that are targets for phosphorylation by GSK-3h.
Phosphorylation of Axin results in protein stabilization, and
phosphorylation of APC results in enhanced binding to h-
catenin. Axin, which functions as a scaffold protein, directly
associates with h-catenin, GSK-3h and APC, and has been
shown to negatively regulate the Wnt signalling pathway
[147,152]. Interaction of GSK-3h with Axin in the complex
facilitates efficient phosphorylation of h-catenin by GSK-
3h. In the presence of Wnt/Wg signalling, Axin and APC are
dephosphorylated, which decreases their ability to bind h-
catenin, leading to its cytoplasmic accumulation [131,153]
(Fig. 4B).
4.4. ILK and regulation of b-catenin/Tcf
Besides the loss of E-cadherin, another means of regu-
lating epithelial and mesodermal cell fate is through certain
Wnt proteins. In fact, the downstream effect of the Wnt
pathway, which is the activation of the h-catenin/LEF(Tcf)
transcription factor, has also been shown to up-regulate
mesenchymal genes [154]. EMT is of critical importance to
the oncogenic and invasive properties of tumour cells
derived from the epithelial origins. As discussed above,
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cell adhesion and cell to ECM interactions also get regu-
lated through ILK. Therefore, the understanding of the
involvement of the components of both pathways in
EMT generated interest in identification of the possible
synergy between ILK and h-catenin/Tcf-mediated activa-
tion of target genes. Indeed, overexpression of ILK in two
independent epithelial systems, IEC-18 intestinal epithelial
cells and scp2 mouse mammary epithelial cells, has been
shown to result in the translocation of h-catenin to the
nucleus in the absence of a significant alteration in its
expression level [31]. In addition, up-regulation of LEF-1
expression has been observed in these ILK overexpressing
epithelial cells, resulting in h-catenin/LEF-1 complex for-
mation, and activation of its transcriptional activity. This
nuclear localization of h-catenin has been demonstrated to
be ILK-specific, and dependent on active kinase form of
ILK, as overexpression of other oncogenes such as H-ras
and v-src as well as kinase-deficient ILK did not result in
such phenotypic changes in these cells [31]. Therefore, it
has been postulated that the ILK-induced activation of h-
catenin/LEF complex formation could influence the expres-
sion of LEF-1/h-catenin-responsive genes such as cyclin
D1 [34].
This finding, which implicates ILK in the activation of
some of the components of the Wnt signalling pathway,
generated interest in the identification of a possible role for
ILK in regulation of some other components of this signalling
pathway. Specifically, ILK has been shown to directly phos-
phorylate GSK-3h (on serine 9) in vitro (Fig. 4B). Also,
stable or transient overexpression of ILK inhibits GSK-3
activity, whereas the overexpression of the kinase-deficient
form of ILK enhances GSK-3h activity [4,13,29,30,34]. The
inhibition of GSK-3h by ILK ultimately results in the sta-
bilization of h-catenin, and an increase in h-catenin/LEF1
transcriptional activity as previously described [4,13,34].
The implication of ILK in Wnt pathway has also been
examined in the background of APC mutation in SW40 and
DLD-1 human colon carcinoma cell lines. In this case,
inhibition of ILK results in a decrease in a nuclear h-catenin
expression, and stimulation of GSK-3h activity, leading to
accelerated degradation of h-catenin, and a substantial
inhibition of h-catenin/LEF1 transcriptional activity
[13,34,155]. In addition, in human colonic polyposis and
colorectal carcinomas, the expression of ILK is coordinately
up-regulated with phosphorylation of GSK-3 and h-catenin
stabilization [47,156]. Targeted overexpression of Wnt-1 in
the mammary gland of transgenic mice has also been shown
to increase both ILK activity and cyclin D1 levels [35].
Moreover, in PTEN-null prostate cancer cells where ILK is
constitutively active [16], constitutively high levels of both
nuclear h-catenin and cyclin D1 have also been observed.
Subsequent transfection of wild-type PTEN, however, has
been shown to stimulate phosphorylation and degradation of
h-catenin in these cells through ILK-mediated activation of
GSK-3h [18].Recently, ILKAP, a protein phosphatase 2C (PP2C), was
identified as a negative regulator of ILK kinase activity [6].
ILKAP has been shown to selectively inhibit activation of
the LEF-1/Tcf transcription factors as the result of inhibition
of GSK-3h phosphorylation on Ser 9. Meanwhile, it shows
no effect on fibronectin-induced phosphorylation of PKB
Ser 473 [6]. This suggests that ILKAP complexes with ILK
to selectively inhibit GSK-3h phosphorylation.
Nonetheless, within the Wnt/h-catenin signalling path-
way, not all cellular effects are dependent on transcription.
Modulation of cell shape and cell adhesion, in particular,
appears to be mediated by transcription-independent branch
of the Wnt/h-catenin pathway [157]. For instance, in C.
elegans, only the upstream components including GSK-3h,
and not h-catenin and LEF/Tcf transcription factors, are
required for correct mitotic spindle orientation [158]. In fact,
a potential role for paxillin–ILK interaction with the cyto-
plasmic components of Wnt/h-catenin pathway, namely dvl,
has also been proposed for this mesenchymal morphogenesis
[157].
Collectively, these data implicate ILK as a key intracel-
lular regulator of signalling via the components of Wnt
signalling pathway, specifically through modulation of
GSK-3h activity (Fig. 4A and B). Despite the multiple
point of cross-talk revealed between ILK and Wnt signal-
ling components, the exact interaction between the two
pathways still remains to be identified. Whether Wnt
signalling also requires ILK for the downstream activation
of the h-catenin/Tcf transcription complex is the subject of
further investigation.
The observation that ILK mediated down-regulation of
E-cadherin results in the redistribution of h-catenin from
the plasma membrane to the nucleus [41] suggests a direct
relationship between E-cadherin regulation and h-catenin
localization through ILK. However, the observed nuclear
localization of h-catenin could be mediated directly by
ILK, independent of E-cadherin, since forced expression of
E-cadherin in these cells has minimal effect on nuclear h-
catenin in ILK overexpressing cells phenotype (unpub-
lished observation). This further supports a direct role for
ILK in regulating the downstream components of the Wnt
pathway.
In conclusion, several studies in recent years have de-
monstrated a significant role for ILK in regulating E-
cadherin and h-catenin/Tcf signalling pathways. These
crucial insights have emerged from the combined studies
using cell biological, molecular, and pharmacological ap-
proaches, as well as animal models of EMT and oncogen-
esis. However, the exact molecular interactions of these
signalling pathways still remain to be identified in the next
few years. Therefore, it is to be anticipated that the more
comprehensive understanding of the precise role of ILK in
mediating the repression of E-cadherin and regulation of h-
catenin will allow for the design of novel, sophisticated
diagnostic and therapeutic tools especially for cancer and
fibrotic diseases.
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